Cullinan Therapeutics Files 8-K on Shareholder Vote Matters

Ticker: CGEM · Form: 8-K · Filed: Jun 27, 2024 · CIK: 1789972

Cullinan Therapeutics, Inc. 8-K Filing Summary
FieldDetail
CompanyCullinan Therapeutics, Inc. (CGEM)
Form Type8-K
Filed DateJun 27, 2024
Risk Levellow
Pages2
Reading Time2 min
Key Dollar Amounts$0.0001
Sentimentneutral

Sentiment: neutral

Topics: shareholder-vote, corporate-governance, filing-update

TL;DR

Cullinan Therapeutics had a shareholder vote on 6/26. Details to follow.

AI Summary

Cullinan Therapeutics, Inc. filed an 8-K on June 27, 2024, reporting on a submission of matters to a vote of security holders that occurred on June 26, 2024. The company, formerly known as Cullinan Oncology, Inc., is based in Cambridge, MA.

Why It Matters

This filing indicates that Cullinan Therapeutics held a vote of its security holders, which could pertain to significant corporate actions or governance changes.

Risk Assessment

Risk Level: low — The filing is a routine disclosure of a shareholder vote and does not contain immediate negative financial or operational news.

Key Players & Entities

  • Cullinan Therapeutics, Inc. (company) — Registrant
  • Cullinan Oncology, Inc. (company) — Former company name
  • June 26, 2024 (date) — Date of earliest event reported
  • June 27, 2024 (date) — Date of report
  • Cambridge, Massachusetts (location) — Principal Executive Offices

FAQ

What specific matters were submitted to a vote of Cullinan Therapeutics' security holders on June 26, 2024?

The filing states that matters were submitted to a vote of security holders on June 26, 2024, but does not specify the exact nature of these matters in the provided text.

When was the 8-K filing submitted to the SEC?

The 8-K filing was submitted on June 27, 2024.

What is the principal executive office address for Cullinan Therapeutics, Inc.?

The principal executive offices are located at One Main Street, Suite 1350, Cambridge, Massachusetts, 02142.

What was Cullinan Therapeutics, Inc. formerly known as?

Cullinan Therapeutics, Inc. was formerly known as Cullinan Oncology, Inc.

What is the Commission File Number for Cullinan Therapeutics, Inc.?

The Commission File Number for Cullinan Therapeutics, Inc. is 001-39856.

Filing Stats: 510 words · 2 min read · ~2 pages · Grade level 13.3 · Accepted 2024-06-27 17:00:09

Key Financial Figures

  • $0.0001 — nge on which registered Common Stock, $0.0001 par value per share CGEM The Nasdaq

Filing Documents

07 Submission of Matters to a Vote of Security Holders

Item 5.07 Submission of Matters to a Vote of Security Holders. The Annual Meeting of Stockholders (the "Annual Meeting") of Cullinan Therapeutics, Inc. (the "Company") was held on June 26, 2024. The stockholders present voted on the two proposals presented at the Annual Meeting as follows. Proposal One — Election of Directors The Company's stockholders elected two Class I directors to the Company's Board of Directors for three-year terms or until her or his successor has been duly elected and qualified, or until her or his earlier death, resignation or removal, by the following votes: Nominee Votes For Votes Withheld Broker Non-Votes Anne-Marie Martin, Ph.D. 25,054,060 11,471,277 4,156,894 David Meek 36,409,849 115,488 4,156,894 Proposal Two — Ratification of Appointment of Independent Registered Accounting Firm The Company's stockholders ratified the appointment of KPMG LLP as the Company's independent registered accounting firm for the fiscal year ending December 31, 2024 by the following votes: Votes For Votes Against Abstentions Broker Non-Votes 40,163,993 516,975 1,263 0

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. CULLINAN THERAPEUTICS, INC. Date: June 27, 2024 By: /s/ Mary Kay Fenton Mary Kay Fenton Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.